Study summary
Two lower-cost versions of Lutathera were approved
What was tested
FDA approval of two versions of lutetium-177 dotatate (Bexlutry from Curium and Bravnetsa from Lantheus), equivalent to Lutathera, for somatostatin-receptor-positive GEP-NETs.
What they found
- Bexlutry was approved through the 505(b)(2) pathway and Bravnetsa as a generic (ANDA).
- Lutathera's original trial showed tumors shrinking in 18% vs 3% with high-dose octreotide.
What it means
More supply and competition may widen access to radioligand therapy.
Last reviewed 2026-11-14 by the Find a Trial editorial team.
Information on this page is for educational purposes and is not medical advice.
Always consult qualified healthcare professionals about clinical trial participation.